Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis

a multicentre, randomised, double-blind, placebo-controlled phase IIb study

G. Comi, A. Pulizzi, M. Rovaris, O. Abramsky, T. Arbizu, A. Boiko, R. Gold, E. Havrdova, S. Komoly, KW Selmaj, B. Sharrack, M. Filippi

Research output: Contribution to journalArticle

231 Citations (Scopus)

Abstract

Background: A 24-week phase II trial has shown that 0·3 mg of laquinimod given daily to patients with relapsing-remitting multiple sclerosis was well tolerated and reduced the formation of active lesions. We assessed the effect of oral daily 0·3 and 0·6 mg laquinimod on MRI-monitored disease activity in a 36-week double-blind, placebo-controlled phase IIb study. Methods: The study was done in 51 centres in nine countries. Inclusion criteria were one or more relapses in the year before entry and at least one gadolinium enhancing (GdE) lesion on screening MRI. Of 720 patients screened, 306 eligible patients were enrolled. Patients, aged 18-50 years, were randomly assigned to placebo (n=102), laquinimod 0·3 mg a day (n=98), or 0·6 mg a day (n=106). Brain MRI scans and clinical assessments were done at week -4, baseline, and monthly from week 12 to week 36. The primary outcome was the cumulative number of GdE lesions at weeks 24, 28, 32, and 36. The principal analysis of the primary endpoint was done on the intention-to-treat cohort. This study is registered with ClinicalTrials.gov, number NCT00349193. Findings: Compared with placebo, treatment with laquinimod 0·6 mg per day showed a 40·4% reduction of the baseline adjusted mean cumulative number of GdE lesions per scan on the last four scans (simple means 4·2 [SD 9·2] vs 2·6 [5·3], p=0·0048); treatment with 0·3 mg per day showed no significant effects (3·9 [5·5] vs placebo, p=0·6740). Both doses of laquinimod were well tolerated, with some transient and dose-dependent increases in liver enzymes. A case of Budd-Chiari syndrome-ie, a thrombotic venous outflow obstruction of the liver-occurred after 1 month of exposure in a patient with underlying hypercoagulability who received 0·6 mg laquinimod. Anticoagulant treatment resulted in a decline of liver enzymes to normal without any clinical signs of hepatic decompensation. Interpretation: In patients with relapsing-remitting multiple sclerosis, 0·6 mg per day laquinimod significantly reduced MRI-measured disease activity and was well tolerated. Funding: Teva Pharmaceutical Industries.

Original languageEnglish
Pages (from-to)2085-2092
Number of pages8
JournalLancet
Volume371
Issue number9630
DOIs
Publication statusPublished - 2008

Fingerprint

Relapsing-Remitting Multiple Sclerosis
Placebos
Gadolinium
Liver
Budd-Chiari Syndrome
Thrombophilia
Drug Industry
Enzymes
laquinimod
Anticoagulants
Therapeutics
Magnetic Resonance Imaging
Recurrence
Brain

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis : a multicentre, randomised, double-blind, placebo-controlled phase IIb study. / Comi, G.; Pulizzi, A.; Rovaris, M.; Abramsky, O.; Arbizu, T.; Boiko, A.; Gold, R.; Havrdova, E.; Komoly, S.; Selmaj, KW; Sharrack, B.; Filippi, M.

In: Lancet, Vol. 371, No. 9630, 2008, p. 2085-2092.

Research output: Contribution to journalArticle

Comi, G. ; Pulizzi, A. ; Rovaris, M. ; Abramsky, O. ; Arbizu, T. ; Boiko, A. ; Gold, R. ; Havrdova, E. ; Komoly, S. ; Selmaj, KW ; Sharrack, B. ; Filippi, M. / Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis : a multicentre, randomised, double-blind, placebo-controlled phase IIb study. In: Lancet. 2008 ; Vol. 371, No. 9630. pp. 2085-2092.
@article{1d86438d15d148e08502cc4d670855db,
title = "Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study",
abstract = "Background: A 24-week phase II trial has shown that 0·3 mg of laquinimod given daily to patients with relapsing-remitting multiple sclerosis was well tolerated and reduced the formation of active lesions. We assessed the effect of oral daily 0·3 and 0·6 mg laquinimod on MRI-monitored disease activity in a 36-week double-blind, placebo-controlled phase IIb study. Methods: The study was done in 51 centres in nine countries. Inclusion criteria were one or more relapses in the year before entry and at least one gadolinium enhancing (GdE) lesion on screening MRI. Of 720 patients screened, 306 eligible patients were enrolled. Patients, aged 18-50 years, were randomly assigned to placebo (n=102), laquinimod 0·3 mg a day (n=98), or 0·6 mg a day (n=106). Brain MRI scans and clinical assessments were done at week -4, baseline, and monthly from week 12 to week 36. The primary outcome was the cumulative number of GdE lesions at weeks 24, 28, 32, and 36. The principal analysis of the primary endpoint was done on the intention-to-treat cohort. This study is registered with ClinicalTrials.gov, number NCT00349193. Findings: Compared with placebo, treatment with laquinimod 0·6 mg per day showed a 40·4{\%} reduction of the baseline adjusted mean cumulative number of GdE lesions per scan on the last four scans (simple means 4·2 [SD 9·2] vs 2·6 [5·3], p=0·0048); treatment with 0·3 mg per day showed no significant effects (3·9 [5·5] vs placebo, p=0·6740). Both doses of laquinimod were well tolerated, with some transient and dose-dependent increases in liver enzymes. A case of Budd-Chiari syndrome-ie, a thrombotic venous outflow obstruction of the liver-occurred after 1 month of exposure in a patient with underlying hypercoagulability who received 0·6 mg laquinimod. Anticoagulant treatment resulted in a decline of liver enzymes to normal without any clinical signs of hepatic decompensation. Interpretation: In patients with relapsing-remitting multiple sclerosis, 0·6 mg per day laquinimod significantly reduced MRI-measured disease activity and was well tolerated. Funding: Teva Pharmaceutical Industries.",
author = "G. Comi and A. Pulizzi and M. Rovaris and O. Abramsky and T. Arbizu and A. Boiko and R. Gold and E. Havrdova and S. Komoly and KW Selmaj and B. Sharrack and M. Filippi",
year = "2008",
doi = "10.1016/S0140-6736(08)60918-6",
language = "English",
volume = "371",
pages = "2085--2092",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Lancet Publishing Group",
number = "9630",

}

TY - JOUR

T1 - Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis

T2 - a multicentre, randomised, double-blind, placebo-controlled phase IIb study

AU - Comi, G.

AU - Pulizzi, A.

AU - Rovaris, M.

AU - Abramsky, O.

AU - Arbizu, T.

AU - Boiko, A.

AU - Gold, R.

AU - Havrdova, E.

AU - Komoly, S.

AU - Selmaj, KW

AU - Sharrack, B.

AU - Filippi, M.

PY - 2008

Y1 - 2008

N2 - Background: A 24-week phase II trial has shown that 0·3 mg of laquinimod given daily to patients with relapsing-remitting multiple sclerosis was well tolerated and reduced the formation of active lesions. We assessed the effect of oral daily 0·3 and 0·6 mg laquinimod on MRI-monitored disease activity in a 36-week double-blind, placebo-controlled phase IIb study. Methods: The study was done in 51 centres in nine countries. Inclusion criteria were one or more relapses in the year before entry and at least one gadolinium enhancing (GdE) lesion on screening MRI. Of 720 patients screened, 306 eligible patients were enrolled. Patients, aged 18-50 years, were randomly assigned to placebo (n=102), laquinimod 0·3 mg a day (n=98), or 0·6 mg a day (n=106). Brain MRI scans and clinical assessments were done at week -4, baseline, and monthly from week 12 to week 36. The primary outcome was the cumulative number of GdE lesions at weeks 24, 28, 32, and 36. The principal analysis of the primary endpoint was done on the intention-to-treat cohort. This study is registered with ClinicalTrials.gov, number NCT00349193. Findings: Compared with placebo, treatment with laquinimod 0·6 mg per day showed a 40·4% reduction of the baseline adjusted mean cumulative number of GdE lesions per scan on the last four scans (simple means 4·2 [SD 9·2] vs 2·6 [5·3], p=0·0048); treatment with 0·3 mg per day showed no significant effects (3·9 [5·5] vs placebo, p=0·6740). Both doses of laquinimod were well tolerated, with some transient and dose-dependent increases in liver enzymes. A case of Budd-Chiari syndrome-ie, a thrombotic venous outflow obstruction of the liver-occurred after 1 month of exposure in a patient with underlying hypercoagulability who received 0·6 mg laquinimod. Anticoagulant treatment resulted in a decline of liver enzymes to normal without any clinical signs of hepatic decompensation. Interpretation: In patients with relapsing-remitting multiple sclerosis, 0·6 mg per day laquinimod significantly reduced MRI-measured disease activity and was well tolerated. Funding: Teva Pharmaceutical Industries.

AB - Background: A 24-week phase II trial has shown that 0·3 mg of laquinimod given daily to patients with relapsing-remitting multiple sclerosis was well tolerated and reduced the formation of active lesions. We assessed the effect of oral daily 0·3 and 0·6 mg laquinimod on MRI-monitored disease activity in a 36-week double-blind, placebo-controlled phase IIb study. Methods: The study was done in 51 centres in nine countries. Inclusion criteria were one or more relapses in the year before entry and at least one gadolinium enhancing (GdE) lesion on screening MRI. Of 720 patients screened, 306 eligible patients were enrolled. Patients, aged 18-50 years, were randomly assigned to placebo (n=102), laquinimod 0·3 mg a day (n=98), or 0·6 mg a day (n=106). Brain MRI scans and clinical assessments were done at week -4, baseline, and monthly from week 12 to week 36. The primary outcome was the cumulative number of GdE lesions at weeks 24, 28, 32, and 36. The principal analysis of the primary endpoint was done on the intention-to-treat cohort. This study is registered with ClinicalTrials.gov, number NCT00349193. Findings: Compared with placebo, treatment with laquinimod 0·6 mg per day showed a 40·4% reduction of the baseline adjusted mean cumulative number of GdE lesions per scan on the last four scans (simple means 4·2 [SD 9·2] vs 2·6 [5·3], p=0·0048); treatment with 0·3 mg per day showed no significant effects (3·9 [5·5] vs placebo, p=0·6740). Both doses of laquinimod were well tolerated, with some transient and dose-dependent increases in liver enzymes. A case of Budd-Chiari syndrome-ie, a thrombotic venous outflow obstruction of the liver-occurred after 1 month of exposure in a patient with underlying hypercoagulability who received 0·6 mg laquinimod. Anticoagulant treatment resulted in a decline of liver enzymes to normal without any clinical signs of hepatic decompensation. Interpretation: In patients with relapsing-remitting multiple sclerosis, 0·6 mg per day laquinimod significantly reduced MRI-measured disease activity and was well tolerated. Funding: Teva Pharmaceutical Industries.

UR - http://www.scopus.com/inward/record.url?scp=45249107267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45249107267&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(08)60918-6

DO - 10.1016/S0140-6736(08)60918-6

M3 - Article

VL - 371

SP - 2085

EP - 2092

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9630

ER -